StockData
Canton Strategic Holdings, Inc. logo

Canton Strategic Holdings, Inc. (CNTN) company profile

CNTNNasdaqFinance ServicesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.42−0.22 (-13.41%)

Close on Nov 17, 2026Market cap $113.15MP/E –Yield –

About Canton Strategic

Finance Services, SIC 6199

Canton Strategic Holdings, Inc. is an enterprise focused on digital asset treasury operations and clinical-stage biotechnology development. The company conducts business through two main operational segments: digital asset treasury management and biotechnology research. Within its digital asset segment, the organization holds Canton Coin, operates as a network validator, and supports the Canton Network to foster institutional blockchain adoption and the digitization of financial markets. In its biotechnology business, it develops drug candidates targeted at inflammatory and immunologic conditions characterized by significant unmet medical need. Because its pharmaceutical pipeline remains in clinical development and its digital asset activities center on network participation and balance sheet management, the filing identifies no commercial customers.

Regarding physical presence and operational scale, the provided filing contains no disclosures concerning the number of operating facilities, employee counts, or international countries of operation. The company maintains its principal executive offices in Red Bank, New Jersey.

Summary of the business section of Canton Strategic's latest annual report, written by StockData.

Company profile

Company

Legal name
Canton Strategic Holdings, Inc.
Headquarters
New York, NY
Address
1460 Broadway 10036
Phone
(212) 210-6006
Employees
12, Dec 31, 2025
Industry
Finance Services
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Rosenberg Rich Baker Berman P.A, Somerset, New Jersey

Stock & identifiers

Ticker
CNTN
Former tickers
THAR until Mar 3, 2026; HILS until Sep 25, 2023
Exchange
Nasdaq
IPO date
Jan 13, 2022
Shares outstanding
80M, Aug 13, 2026
Public float
$6.40M, Jun 30, 2025
Filer category
<br>Emerging growth company
Stock splits
1-for-15 reverse, May 28, 2024; 1-for-25 reverse, Nov 21, 2023
SEC CIK
1861657
CUSIP
432705200
ISIN
US4327052001
FIGI
BBG012QFR2V4
Share class FIGI
BBG012QFR3P9
LEI
52990040X8C60JYNXZ70
EIN
84-2642541

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Mark Paul WendlandChief Executive Officer, Director–
Sanam ParikhCOO, Director1,770
Sireesh AppajosyulaCEO, Director66,771
Vincent S. LoPrioreExecutive Chairman, Director732,424
Randy MilbyCEO, Director17,534
Mark Christopher ToomeyPresident–
Angela Dominy RadkowskiChief Operating Officer–
Jacob AsburyChief Financial Officer–
Dong KimCFO–
Sean GalvinDirector–
William Thomas Wiley Jr.Director–
Jill E. SommersDirector–
Rishi NangaliaDirector–
Pamela L. CarterDirector–
Thomas Clay KahlerDirector–
Gary S. StetzDirector134,175
Nancy Davis RickelDirector–
James Gordon LiddyDirector–
Kelly AndersonDirector6,300

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Mark Wendland
Chief Executive Officer (1)
$83.33K$275.00K––$358.33K–
Mark Toomey
President (2)
$83.33K$125.00K––$208.33K–
Jacob Asbury
Chief Financial Officer (3)
$22.50K$7.67K––$30.17K–
Randy Milby
Former Chief Executive Officer (4)
$357.50K–$121.11K$139.85K$618.46K-36%
Sireesh Appajosyula
Former Interim Chief Financial Officer, Chief Operating Officer and Chief Executive Officer (5)
$376.26K$2.29M$214.32K$5.97K$2.88M+311%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 13, 2022
Offer price
$4.00
Securities offered
3,750,000
Gross proceeds
$15.00M
Exchange
Nasdaq
First trading day
Jan 12, 2022
First-day close
$3.48-13.0%
Lock-up ends (est.)
Jul 11, 2022

“The initial public offering price of our common stock is $4.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“currently employ 12 full-time employees.”

Corporate history

Events identified from SEC filings

DateEventDetails
Jul 23, 2026Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 11, 2026Name changeName changed from Tharimmune, Inc. to Canton Strategic Holdings, Inc.
Jan 15, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 4, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 16, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 12, 2023Name changeName changed from Hillstream BioPharma Inc. to Tharimmune, Inc.
Jul 17, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 20, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Jun 16, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 16, 2023Late filingNotification of late filing
Oct 28, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 1, 2022Late filingNotification of late filing
Jan 13, 2022IPOInitial public offering priced (424B4 prospectus)
Jan 10, 2022ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?